Company Description
Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for...
Key Icagen Financials
| Company Type | Public - NASDAQ (GM): ICGN Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $21.1 |
| 2005 Employees | 72 |
More Icagen Financials (11 pages)
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Icagen's competition across multiple industries
Top Icagen Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Icagen Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Charles A. Sanders | Network | E-mail |
| President, CEO, and Director | P. Kay Wagoner | Network | E-mail |
| EVP Finance and Corporate Development, CFO, and Treasurer | Richard D. Katz | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Icagen News
- Icagen Inc. (ICGN) Corporate Event Announcement Notice [Wall Street Horizon] (18 Jul 2008 21:14:00 EDT)
- Icagen Inc. (ICGN) Corporate Event Announcement Notice [Wall Street Horizon] (17 Jul 2008 21:16:00 EDT)
- Icagen Inc. (ICGN) Corporate Event Announcement Notice [Wall Street Horizon] (10 Jul 2008 21:02:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.